Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab

摘要: Purpose: We evaluated the prognostic and predictive use of circulating VEGF-A levels in phase III trials bevacizumab colorectal cancer, lung renal cell carcinoma. Methods: Baseline plasma samples from 1,816 patients were analyzed for using an ELISA, which recognizes major isoforms with equivalent sensitivity. HR 95% confidence intervals (CI) study end points estimated Cox regression analysis. A subset matched archival tumor was expression situ hybridization. Results: Higher showed trends toward adverse significance control arms multiple trials, reaching statistical overall survival (OS) AVF2107 (highest vs. lowest 50%: = 1.76; CI, 1.28–2.41), AVAiL (HR 1.52; 1.16–2.00), AVOREN 1.67; 1.18–2.36). In analyses, HRs progression-free similar across low high subgroups favored bevacizumab-containing treatment. subgroups, (95% CIs) 0.61 (0.43–0.87) AVF2107, 0.71 (0.43–1.16) E4599, 0.74 (0.59–0.94) (low-dose), 0.89 (0.70–1.13) (high-dose), 0.56 (0.40–0.78) AVOREN. Analyses OS data have shown results. No correlation between primary observed. Conclusions: this comprehensive evaluation, pretreatment total outcome metastatic colorectal, lung, cancers, but it not bevacizumab-based treatment benefit. Clin Cancer Res; 19(4); 929–37. ©2012 AACR .